Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: C

Drug products: Forxiga, Xigduo

ATC code: A10BD15, A10BK01

Substances: dapagliflozin, dapagliflozin propanediol monohydrate


Only 35% women were included in the study population in the large clinical trials on SGLT 2 inhibitors. Dapagliflozin as monotherapy or in combination with other glucose lowering medication reduces HbA1c levels to the same extent in both men and women. Meta analyses on SGLT2 inhibitors show no difference between men and women, in regard to cardiovascular efficacy outcomes or death, hospitalization due to congestive heart failure and progression of nephropathy.

Compared with placebo, both men and women treated with dapagliflozin is at increased risk of urinary tract infections and mycotic genital infection. Individuals with a history of chronic or recurrent urinary tract infections or genital mycotic infections are more likely to experience such infections.

Men are twice as likely to fill a prescription for dapagliflozin in Sweden, compared with women.

In a randomized controlled trial, men had a greater total body weight loss compared to women when treated with dapagliflozin.

Additional information

For type 1 diabetes mellitus when diagnosed under the age of 15, the prevalence between boys and girls is similar. In adult populations of patients with both type 1 and 2 diabetes, the differences between the sexes in prevalence seem to vary depending on several factors such as incidence of disease, age groups and ethnicities studied.  Studies indicate that men in the early middle age display a higher prevalence of type 2 diabetes mellitus compared with women in the same age group [1]. In a nationwide population-based pharmaco-epidemiological study in Sweden, the total age-standardized prevalence of pharmacologically and non-pharmacologically treated diabetes (2012) was 56% for men and 39% for women [2].In Sweden, men are 80% more likely to use sodium-glucose-cotransporter 2 (SGLT2) inhibitors compared to women [3]. In a nationwide cohort study from the US, men and women were as likely to start SGLT2 inhibitor treatment when initiating a glucose lowering medication [4].

Pharmacokinetics and dosing

Pooled data from clinical pharmacology studies (349 men, 89 women) showed that women had a greater mean dapagliflozin AUC of 23%, even though Cmax was not increased [5]. In a population pharmacokinetic model (634 men, 619 women), mean dapagliflozin AUC at steady state was 22% higher in women than in men [5]. These differences have not been found to have any clinically relevant impact and therefore no dose adjustment has been considered necessary according to patient’s sex [6].

Data from three clinical studies of single-dose (2.5, 5 and 10 mg) orally administered dapagliflozin in both adult (39 men, 27 women) and pediatric (24 boys, 15 girls) patients with type 2 diabetes mellitus were analyzed to examine the relationship between dapagliflozin exposure and response. A comparable exposure-response relationship of dapagliflozin was found for both the adult and pediatric patients, and a patient's sex was identified as a significant covariate on dapagliflozin maximum effect (Emax) [7].


According to clinical studies performed by the original manufacturer, treatment with dapagliflozin as monotherapy and in combination with metformin, glimepiride, pioglitazone, sitagliptin, or insulin reduced HbA1c at week 24 compared to control in both men and women [6]. Pooled data from several phase III studies show minimal differences in efficacy between men and women (data not shown) [5]. However, Korean post-marketing surveillance data from a longitudinal prospective study on patients (982 men, 1025 women) with type 2 diabetes mellitus who were prescribed dapagliflozin (10 mg/day) showed a stronger HbA1c reduction in men compared to women [8].

The effects of SGLT2 inhibitors in type 2 diabetes in men and women were assessed in a study including the patients in the four cardiovascular outcome trials (EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI-58 and CREDENCE trials). There was no sex difference in the risk ratios, SGLT2 inhibitors vs control, for cardiovascular efficacy outcomes or death. In all the 4 trials included in the study there were fewer women than men: CANVAS Program 35.8% women, CREDENCE trial 33.9% women, EMPA-REG OUTCOME trial 28.8%, and DECLARE-TIMI-58 trial 37.4% [9].

Adverse effects

SGLT2 inhibitor treatment was associated with similar relative risks in men and women for the safety outcomes of amputation, fracture, genital infection and urinary tract infection when analyzing data from four cardiovascular outcome trials [9].

Data from randomized placebo-controlled clinical trials report a higher frequency of genital mycotic infections and urinary tract infections in women than men treated with dapagliflozin. Genital mycotic infections incidence rates vary from 4.3-13.2% in women and 2.0-3.3% in men. Urinary tract infections incidence rates vary from 2.8-11.9% in women and 2.0-3.5% in men. The incidence of infections was not dose-related [10-16]. In the professional patient advice for dapagliflozin, it is stated that patients with a history of genital mycotic infections or uncircumcised males are at greater risk [6].

In an observational study with data from UK primary care, genital infections that occurred within the first month of treatment were associated with a 50% increased risk for subsequent discontinuation with both SGLT2 inhibitors and DPP4 inhibitors [17].

A population-based cohort study with new-user design evaluated the risk for diabetic ketoacidosis associated with SGLT-2 inhibitors (122 281 men, 86 476 women), using health care data from Canada and the United Kingdom. Dapagliflozin was associated with a 1.86 risk increase compared with DPP-4 inhibitors (121 991 men, 86 766 women) which served as reference. No difference in risk among men and women was shown [18].  

In a study assessing the safety of dapagliflozin in 5405 men and 3169 women, the frequencies of fractures and malignancies were balanced between the dapagliflozin and placebo patient group, and with no difference  found between men and women [19].

The incidence of reported episodes of atrial fibrillation and atrial flutter from high-risk patients with type 2 diabetes mellitus in the DECLARE-TIMI-58 trial was decreased by dapagliflozin treatment. No effect modification was seen by patient’s sex [20].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

An international randomized, double-blind, placebo-controlled Phase III study (100 men, 80 women) showed a greater decrease in total body weight in men (-2.8 kg) at 24 weeks with dapagliflozin compared to women (-1.2 kg) [11].

Updated: 2021-02-12

Date of litterature search: 2020-10-26


  1. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44(1):3-15. PubMed
  2. Jansson SP, Fall K, Brus O, Magnuson A, Wändell P, Östgren CJ et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med. 2015;32(10):1319-28. PubMed
  3. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk
  4. McCoy RG, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, Shah ND. Adoption of New Glucose-Lowering Medications in the US-The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technol Ther. 2019;21(12):702-712. länk
  5. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2. Clin Pharmacokinet 2013 Oct 9; PubMed
  6. FARXIGA (dapagliflozin). DailyMed [www]. US National Library of Medicine. [updated 2020-05-05, cited 2020-10-26]. länk
  7. Parkinson J, Tang W, Johansson CC, Boulton DW, Hamrén B. Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18(7):685-92. PubMed
  8. Han E, Kim A, Lee SJ, Kim JY, Kim JH, Lee WJ, Lee BW. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea. Diabetes Ther. 2018;9(4):1689-1701. PubMed
  9. Rådholm K, Zhou Z, Clemens K, Neal B, Woodward M. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab. 2020;22(2):263-266. PubMed
  10. Bailey CJ, Iqbal N, T'joen C, List JF. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14:951-9. PubMed
  11. Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020-31. PubMed
  12. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405-15. PubMed
  13. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473-8. PubMed
  14. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:479-84. PubMed
  15. Thong KY, Yadagiri M, Barnes DJ, Morris DS, Chowdhury TA, Chuah LL, Robinson AM, Bain SC, Adamson KA, Ryder REJ; ABCD Nationwide Dapagliflozin Audit contributors. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. Prim Care Diabetes. 2018;12(1):45-50. länk
  16. Engelhardt K, Ferguson M, Rosselli JL. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors. Ann Pharmacother. 2020;1060028020951928. PubMed
  17. McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Dennis JM; MASTERMIND consortium. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020;8(1):e001238. länk
  18. Douros A, Lix LM, Fralick M, Dell'Aniello S, Shah BR, Ronksley PE et al. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. Ann Intern Med. 2020;173(6):417-425. PubMed
  19. Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I et al. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab. 2020;22(8):1357-1368. PubMed
  20. Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227-1234. PubMed

Authors: Diana Rydberg

Reviewed by: Carl-Olav Stiller

Approved by: Karin Schenck-Gustafsson